Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07171034
PHASE1

A Phase I Study of KLA318-2 Nanocrystal Injection

Sponsor: Hunan Kelun Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety,tolerability and pharmacokinetics properties of KLA318-2 Nanocrystal Injection after a single intravenous injection in healthy participants.

Official title: A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KLA318-2 Nanocrystal Injection in Healthy Participants

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

48

Start Date

2025-09-01

Completion Date

2026-05-31

Last Updated

2025-11-17

Healthy Volunteers

Yes

Interventions

DRUG

KLA318-2 Nanocrystal Injection

Intravenous injection, single dose

DRUG

Celebrex Capsule

P.O., single dose

Locations (1)

The first affiliated hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital)

Jinan, Shandong, China